Riluzole tablet ( DrugBank: Riluzole )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症3

2. 筋萎縮性側索硬化症


臨床試験数 : 645 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ITMCTR2100004558
2021-03-012021-03-09A multicenter, randomized, double-blind, positive drug parallel controlled clinical trial to evaluate the efficacy and safety of Huolingshengji Keli granules for the treatment of amyotrophic lateral sclerosis (ALS).A multicenter, randomized, double-blind, positive drug parallel controlled clinical trial to evaluate the efficacy and safety of Huolingshengji Keli granules for the treatment of amyotrophic lateral sclerosis (ALS). Amyotrophic lateral sclerosisexperimental group:Huoling Shengji Keli granules 1 bag + riluzole tablets simulant 1 tablet each time, Bid, oral;control group:Huoling Shengji Keli granules simulant 1 bag + riluzole tablets 1 tablet each time, Bid, oral;Peking University Third HospitalNULLRecruiting4570Bothexperimental group:72;control group:72;Phase 2China
2ChiCTR2100044085
2021-03-012021-03-09A multicenter, randomized, double-blind, positive drug parallel controlled clinical trial to evaluate the efficacy and safety of Huolingshengji Keli granules for the treatment of amyotrophic lateral sclerosis (ALS).A multicenter, randomized, double-blind, positive drug parallel controlled clinical trial to evaluate the efficacy and safety of Huolingshengji Keli granules for the treatment of amyotrophic lateral sclerosis (ALS). Amyotrophic lateral sclerosisexperimental group:Huoling Shengji Keli granules 1 bag + riluzole tablets simulant 1 tablet each time, Bid, oral;control group:Huoling Shengji Keli granules simulant 1 bag + riluzole tablets 1 tablet each time, Bid, oral;Peking University Third HospitalNULLRecruiting4570Bothexperimental group:72;control group:72;Phase 2China
3NCT04950933
(ClinicalTrials.gov)
June 1, 202027/6/2021The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji GranulesA Multi-center, Randomized, Double-blind, Positives Parallel Controlled, Phase ? Clinical Trial to Evaluate the Efficacy and Safety of Huollingshengji Granules in the Treatment of Amyotrophic Lateral Sclerosis (Spleen qi Deficiency, Kidney Yang Deficiency Syndrome)Amyotrophic Lateral SclerosisDrug: Huolingshengji Granules;Drug: Riluzole tabletPeking University Third HospitalThe Second Hospital of Hebei Medical UniversityRecruiting45 Years70 YearsAll144Phase 2/Phase 3China